boehringer ingelheim glp-1 ๐จ Survodutide, a weekly subcutaneous dual GLP-1/glucagon agonist, posts new top-line Phase 3 results today ๐ SYNCHRONIZE-1: Adults with overweight/obesity randomized to survodutide vs. placebo for 76 weeks โ๏ธ 16.6% weight loss ( Boehringer's GLP-1 dual agonist survodutide
Pay in 4 interest-free payments of $5.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Oct 29 - Nov 3





.png)






















